Canadian producer Tilray Brands, Inc. (TSX: TLRY) (Nasdaq: TLRY) says the first batch of its EU-GMP-certified medical cannabis products are being sold in pharmacies across Malta.
On Thursday, the company said its Tilray Medical division completed the premier sale.
“As demand for cannabis continues to grow across Europe, we’re incredibly proud to partner with established and reliable distribution partners to supply new markets with high-quality medical cannabis which patients can rely on,” Tilray’s CSO Denise Faltischek said in a statement.
Maltese patients can get prescriptions for non-smoking forms of medical cannabis, and a medical cannabis card through a family doctor. The cards are issued by Malta’s Superintendent of Public Health.
In December, Malta became the first country in the European Union to pass a cannabis reform bill that legalized recreational cannabis use, cultivation and possession for adults.
A limited list of qualifying conditions for medical cannabis in the country include chronic pain, spasticity from multiple sclerosis and side effects from chemotherapy.
Mugglehead has reached out to Tilray for more information.
Read more: Malta passes EU’s first cannabis bill legalizing personal use and cultivation
Read more: Malta advances cannabis reform bill for cultivation
Follow Natalia Buendia Calvillo on Twitter
natalia@mugglehead.com
